Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
latest_posts
- 1
The Following Huge Thing: 5 Progressive Tech New businesses - 2The Most Enrapturing Authentic Milestones to Visit
- 37 Espresso Machines for Home Baristas
- 4Figure out how to Keep up with Your Dental Inserts for Long haul Achievement
- 5Explainer-What has happened to the damaged spacecraft at China's space station?
- Israel reports first missile fire from Yemen since start of Iran war
- From Sea shores to Urban areas: Astonishing Worldwide Travel Objections
- Instructions to Keep up with Your Traded Teeth for Life span
- Figure out How to Amplify Innovation and Infotainment Frameworks for Senior Drivers in SUVs
- CMA Awards 2025: Full list of nominations, from Entertainer of the Year to Album of the Year
- Instructions to Floss Appropriately and Forestall Gum Sickness
- Vote in favor of your #1 sort of juice
- 4 well known subjects in school
- The 3 little words TV fans can't stop obsessing over
